We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Draft Guidance Clarifies Need for Postmarket Studies
FDA Draft Guidance Clarifies Need for Postmarket Studies
The FDA may approve devices whose benefit-to-risk ratio is less certain if that uncertainty is “sufficiently balanced” by other factors such as postmarket controls, the agency says in draft guidance published Wednesday.